Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Finlabo SIM Spa
|
$58.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bayer AG Gets EU Approval For Contraceptive Jaydess-Reuters
Reuters reported that Bayer AG has received green light for new long-term contraceptive jaydess in the European Union. Further details were not disclosed.
Latest Developments for Bayer AG
- Bayer AG To Acquire Herbal Medicine Maker Steigerwald Arzneimittelwerk GmbH-Reuters
- Bayer AG Gets FDA Approval For Advanced Prostate Cancer Drug; Bayer AG And Algeta ASA To Co-Promote Xofigo in United States-DJ
- Bayer AG's Bayer HealthCare LLC To Acquire Conceptus, Inc
- Bayer AG Confirms FY 2013 Sales Guidance
Latest Key Developments in Pharmaceuticals
- AmerisourceBergen Corp Reaffirms FY 2013 EPS Gudiance-Conference Call
- Immunotec Inc Announces New CEO
- Novo Nordisk A/S Reports Positive Results from First Phase 3 Trial with Long-Acting Factor IX for Treatment of Haemophilia B
- Sanofi SA Announces Positive Results on Pivotal Study of Inhibitor in Myelofibrosis-DJ
- Share this
- Link this
- Digg this
Follow Reuters